Plasmodium vinckei: Optimization of desferrioxamine B delivery in the treatment of murine malaria

Experimental Parasitology

Volumn 89, Issue 3, 1998, Pages 323-330

  Postma, N S ^a   Hermsen, C C ^b   Zuidema, J ^a   Eling, W M C ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; LIPOSOME;

ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MALARIA; MOUSE; NONHUMAN; PARASITEMIA; PLASMODIUM VINCKEI; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; SURVIVAL TIME;

ANIMALIA; MURINAE; PLASMODIUM VINCKEI; PROTOZOA;

EID: 0032128179     PISSN: 00144894     EISSN: None     Source Type: Journal    
DOI: 10.1006/expr.1998.4282     Document Type: Article

References (37)

1. Bate C. A. W., Taverne J., Bootsma H. J., Mason R. C. StH., Skalko N., Gregoriadis G., Playfair J. H. L. Antibodies against phosphatidylinositol and inositol monophosphate specifically inhibit tumour necrosis factor induction by malaria exoantigens. Immunology. 76:1992;35-41.
2. Boelaert J. R. Iron and infection. Acta Clinica Belgica. 51:1996;213-221.
3. Bunnag D., Poltera A. A., Viravan C., Looareesuwan S., Harinasuta K. T., Schindlery C. Plasmodicidal effect of desferrioxamine B in human vivax and falciparum malaria from Thailand. Acta Tropica. 52:1992;59-67.
4. Cabantchik Z. I., Glickstein H., Golenser J., Loyevsky M., Tsafack A. Iron chelators: Mode of action as antimalarials. Acta Haematologica. 95:1996;70-77.
5. Clyde D. F. Recent trends in the epidemiology and control of malaria. Epidemiological Reviews. 9:1987;219-243.
6. Eling W., Jerusalem C. Active immunisation against the malaria parasitePlasmodium bergheiP. berghei. Tropenmedizin und Parasitologie. 28:1977;158-174.
7. Fritsch G., Treumer J., Spira D. T., Jung A. Plasmodiumvinckei. Experimental Parasitology. 60:1985;171-174.
8. Gabutti V., Piga A. Results of long-term iron-chelating therapy. Acta Haematologica. 95:1996;26-36.
9. Golenser J., Tsafack A., Amichai Y., Libman J., Shanzer A., Cabantchik Z. I. Antimalarial action of hydroxamate-based iron chelators and potentiation of desferrioxamine action by reversed siderophores. Antimicrobial Agents and Chemotherapy. 39:1995;61-65.
10. Golenser J., Domb A., Teomim D., Tsafack A., Nisim O., Ponka P., Eling W., Cabantchik Z. I. The treatment of animal models of malaria with iron chelators by use of a novel polymeric device for slow drug release. The Journal of Pharmacology and Experimental Therapeutics. 281:1997;1127-1135.
11. Gordeuk V., Thuma P., Brittenham G., McLaren C., Parry D., Backenstose A., Biemba G., Msiska R., Holmes L., McKinley E., Vargas L., Gilkeson R., Poltera A. A. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. The New England Journal of Medicine. 327:1992;1473-1477.
12. Guilmette R. A., Cerny E. A., Rahman Y. E. Pharmacokinetics of the iron chelator desferrioxamine as affected by liposome encapsulation: Potential in treatment of chronic hemosiderosis. LifeSciences. 22:1978;313-319.
13. Hamilton K. O., Stallibrass L., Hassan I., Halleux C., Mackay M. The transport of two iron chelators, desferrioxamine B and L1, across Caco-2 monolayers. British Journal of Haematology. 86:1994;851-857.
14. Hershko C., Peto T. E. A. Deferoxamine inhibition of malaria is independent of host iron status. Journal of Experimental Medicine. 168:1988;375-387.
15. Hershko C., Gordeuk V. R., Thuma P. E., Theanacho E. N., Spira D. T., Hider R. C., Peto T. E. A., Brittenham G. M. The antimalarial effect of iron chelators: Studies in animal models and in humans with mild falciparum malaria. Journal of Inorganic Biochemistry. 47:1992;267-277.
16. Hider R. C., Choudhury R., Rai B. L., Dehkordi L. S., Singh S. Design of orally active iron chelators. Acta Haematologica. 95:1996;6-12.
17. Hoffbrand A. V. Oral iron chelation. Seminars in Hematology. 33:1996;1-8.
18. Kadir F., Zuidema J., Crommelin D. J. A. Liposomes as drug delivery systems for intramuscular and subcutaneous injections. Particulate Drug Carriers in Medical Applications. 1993;Marcel Dekker, New York. p. 165-198.
19. Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Annals of the New York Academy of Sciences. 119:1964;758-768.
20. Kontoghiorghes G. J. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs. Toxicology Letters. 80:1995;1-18.
21. Lau E. H., Cerny E. A., Rahman Y. E. Liposome-encapsulated desferrioxamine in experimental iron overload. British Journal of Haematology. 47:1981;505-518.
22. Mabeza G. F., Biemba G., Gordeuk V. R. Clinical studies of iron chelators in malaria. Acta Haematologica. 95:1996;78-86.
23. Nastruzzi C., Walde P., Menegatti E., Gambari R. Differential effects of liposome-entrapped desferrioxamine on proliferation and erythroid differentiation of murine erythroleukemic Friend cells. Biochimica et Biophysica Acta. 1013:1989;36-41.
24. Pollack S., Rossan R. N., Davidson D. E., Escajadillo A. Desferrioxamine suppressesPlasmodium falciparum. Proceedings of the Society for Experimental Biology and Medicine. 184:1987;162-164.
25. Postma N. S., Mommers E. C., Eling W. M. C., Zuidema J. Oxidative stress in malaria: Implications for prevention and therapy. Pharmacy World and Science. 18:1996;121-129.
26. Rouser G., Fluscher S., Yamamoto A. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids. 5:1970;494-496.
27. Scheibel L. W., Stanton G. G. Antimalarial activity of selected aromatic chelators. IV. Cation uptake byPlasmodium falciparum. Molecular Pharmacology. 30:1986;364-369.
28. Scott M. D., Ranz A., Kuypers F. A., Lubin B. H., Meshnick S. R. Parasite uptake of desferrioxamine: A prerequisite for antimalarial activity. British Journal of Haematology. 75:1990;598-602.
29. Seligman P. A., Kovar J., Gelfand E. W. Lymphocyte proliferation is controlled by both iron availability and regulation of iron uptake pathways. Pathobiology. 60:1992;19-26.
30. Storm G., Oussoren C., Peeters P. A. M., Barenholz Y. Tolerability of liposomesin vivo. Gregoriadis G. Liposome Technology. 3:1993;345-383 CRC Press, Boca Raton.
31. Szoka F., Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proceedings of the National Acadamy of Sciences USA. 75:1978;4194-4198.
32. Tabak A., Hoffer E., Taitelman U. Evaluation of a liposome system for the delivery of desferrioxamine to lungs in rats. Journal of Pharmaceutical Pharmacology. 46:1994;789-796.
33. Traore O., Carnevale P., Kaptue-Noche L., M'Bede J., Desfontaine M., Elion J., Labie D., Nagel R. L. Preliminary report on the use of desferrioxamine in the treatment ofPlasmodium falciparum. American Journal of Hematology. 37:1991;206-208.
34. Tsafack A., Libman J., Shanzer A., Cabantchik Z. I. Chemical determinants of antimalarial activity of reversed siderophores. Antimicrobial Agents and Chemotherapy. 40:1996;2160-2166.
35. Van Zyl R. L., Havlik I., Hempelmann E., MacPhail A. P., McNamara L. Malaria pigment and extracellular iron: Possible target for iron chelating agents. Biochemical Pharmacology. 45:1993;1431-1436.
36. Weiss G., Wachter H., Fuchs D. Linkage of cell-mediated immunity to iron metabolism. Immunology Today. 16:1995;495-499.
37. Young S. P., Baker E., Huehns E. R. Liposome entrapped desferrioxamine and iron transporting ionophores: A new approach to iron chelation therapy. British Journal of Haematology. 41:1979;357-363.